EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 162 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,602 | +69.9% | 1,370 | +109.5% | 0.00% | – |
| Q2 2023 | $12,712 | +797.1% | 654 | +1208.0% | 0.00% | – |
| Q1 2023 | $1,417 | +41.7% | 50 | -5.7% | 0.00% | – |
| Q4 2022 | $1,000 | 0.0% | 53 | -5.4% | 0.00% | – |
| Q3 2022 | $1,000 | -75.0% | 56 | -42.9% | 0.00% | – |
| Q2 2022 | $4,000 | -20.0% | 98 | 0.0% | 0.00% | – |
| Q1 2022 | $5,000 | -70.6% | 98 | -70.1% | 0.00% | – |
| Q4 2021 | $17,000 | -10.5% | 328 | -3.8% | 0.00% | – |
| Q3 2021 | $19,000 | +35.7% | 341 | 0.0% | 0.00% | – |
| Q2 2021 | $14,000 | -17.6% | 341 | -20.5% | 0.00% | – |
| Q1 2021 | $17,000 | -15.0% | 429 | +4.6% | 0.00% | – |
| Q4 2020 | $20,000 | +33.3% | 410 | -0.2% | 0.00% | – |
| Q3 2020 | $15,000 | +25.0% | 411 | +58.1% | 0.00% | – |
| Q2 2020 | $12,000 | +9.1% | 260 | +18.7% | 0.00% | – |
| Q1 2020 | $11,000 | – | 219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |